Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the type 2 diabetes drug market will exceed $15 billion in 2013. The new Pharmacor study entitled Type 2 Diabetes also states that novel therapies will capture approximately 25% of the market in 2013. Sales of inhaled insulin will exceed $1.3 billion in 2013, largely as a result of its high price rather than the number of drug-treated patients.

"We expect both Nektar/Pfizer/Sanofi-Aventis's Exubera and Aradigm/Novo Nordisk's AERx inhaled insulin technology to reach the market in 2007," said Carole Gleeson, analyst, Decision Resources. "However, Exubera has faced some difficulty in Europe, where the EMEA has requested further safety data. Despite significant concerns about long-term safety, cost, and dosing variability, the consensus among thought leaders is that an inhaled formulation may allow earlier initiation of insulin therapy, a change that will likely reduce the probability of diabetic complications."

About Type 2 Diabetes

The International Diabetes Foundation recently warned that type 2 diabetes has become a global pandemic and one of the most challenging public health problems of the 21st century. A progressive disease of metabolic dysregulation, type 2 diabetes is characterized by insulin resistance and impaired insulin secretion. Over the past decade, the prevalence of this complex disease soared in the United States, and it is expected to continue growing in the near future as the adult population increases in number.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Sanofi-Aventis's Acomplia to Have Huge Impact on the Obesity Drug Market

View Now